2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
5
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Shock, Septic
1
Sepsis
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Fluorouracil
219
Leucovorin
202
Oxaliplatin
192
Irinotecan
150
Bevacizumab
110
Capecitabine
94
Cetuximab
90
Folfox protocol
54
Chemotherapy, Adjuvant
36
Panitumumab
30
Colonoscopy
30
pembrolizumab
23
Drug Therapy
23
Nivolumab
22
Magnetic Resonance Spectroscopy
22
Gemcitabine
21
Blood Specimen Collection
20
Radiotherapy
19
Floxuridine
19
Biopsy
19
Neoadjuvant Therapy
18
Laparoscopy
18
IFL protocol
18
Early Intervention, Educational
18
Celecoxib
18
Surveys and Questionnaires
17
Surgical Procedures, Operative
16
Immunohistochemistry
16
Exercise
16
trifluridine tipiracil drug combination
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
×
Clear all
NCT00574678
2021-08-05
ACT
University of Arkansas
Phase 1/2
Completed
150 enrolled